Phase 1 Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and COPD and/or CHF

A

Acusphere

Status and phase

Completed
Phase 1

Conditions

Chronic Obstructive Pulmonary Disease
Congestive Heart Failure

Treatments

Drug: AI-700

Study type

Interventional

Funder types

Industry

Identifiers

NCT00156780
AI-700-05

Details and patient eligibility

About

This study was conducted to evaluate the safety and pharmacokinetics of an echocardiographic contrast agent, AI-700, in patients with moderate to severe chronic obstructive pulmonary disease (COPD) and/or congestive heart failure (CHF).

Full description

In ongoing clinical trials, AI-700 is currently being evaluated for its value to provide enhanced echocardiography to detect CAD. The patient population is comprised of those patients who have chest pain and are being evaluated for inducible ischemia. This population may include patients with compromised pulmonary function due to COPD or CHF. This study was to evaluate the safety of AI-700 in these patients.

Sex

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Trial design

Primary purpose

Educational/Counseling/Training

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems